🔍

Krebs Biochemicals and Industries Limited (KREBSBIO)

₹60.19 -1.04% last close, 16 Oct

📊 NSE: KREBSBIO 🏢 Pharmaceuticals - Indian - Bulk Drugs 📢 Latest filing: 29 Sep 2026 📝 Analysis written: 14 Dec 2025

Q2 FY27 results

📅 Next results: 29 Oct 2026 (board meeting)

Krebs Biochemicals and Industries Limited's board meets on 29 Oct 2026 to consider its Q2 FY27 results (July-September 2026).

In its latest reported quarter, Q1 FY27, Krebs Biochemicals' revenue was ₹7.0 Cr (+27.4% year on year, +2.6% on the previous quarter), and net profit ₹-2.5 Cr (a smaller loss than a year earlier); the operating margin was 11.8%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹7.0	+27.4%	+2.6%
Operating profit	₹0.8	from loss	from loss
Net profit	₹-2.5	loss narrowed	loss widened
EPS (₹)	-1.15	loss narrowed	loss widened
Operating margin	11.8%	—	—

Full quarterly financials → Results calendar →

KREBSBIO delivery percentage and bulk deals

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 65.89% of the KREBSBIO shares traded on NSE were taken to delivery, against the stock's own 20-session average of 57.46%. That is close to its usual level. Turnover was only ₹5 lakh, so a handful of trades can move this figure. Volume was 0.2 times its average, well below normal. 2 bulk or block deals were reported in KREBSBIO in the last 60 days: ₹0.01 Cr bought and ₹0.80 Cr sold.

65.89%Delivery, 16 Oct

57.46%Own 20-session average

0.2×Volume vs its average

₹60.19NSE close · -1.04%

Delivery in the last 5 sessions: 75.4% · 35.0% · 45.0% · 53.0% · 65.9%

Date	Side	Counterparty	Value	Price	Quantity	Type
1 Oct	Sell	Vaibhav Upadhyay	₹0.80 Cr	₹66.69	120,268	Bulk
1 Oct	Buy	Vaibhav Upadhyay	₹0.01 Cr	₹66.78	742	Bulk

Delivery across the market →All bulk and block deals →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

Krebs Biochemicals Shareholders Approve All 5 Resolutions at 34th AGM, Including Ipca RPT

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Sep 2026, 07:10 PM

Krebs Biochemicals and Industries Limited announced that all 5 ordinary resolutions proposed at its 34th Annual General Meeting on September 29, 2026, were approved by shareholders with requisite majority. The approved resolutions include the adoption of FY26 financial statements, reappointment of directors Dr. R T Ravi and Mr. Manish Kumar Jain, and ratification of cost auditor remuneration. Significantly, shareholders approved related-party transactions with promoter group entity IPCA Laboratories Limited with 96.58% votes in favor.

All 5 ordinary resolutions passed by requisite majority at the 34th AGM held on September 29, 2026
Approval of related party transactions with IPCA Laboratories Limited passed with 96.58% votes in favor (1,56,71,588 votes) and 3.42% against
Adoption of audited financial statements for FY ended March 31, 2026 passed with 99.99% approval (1,56,77,688 votes)
Reappointment of directors Dr. R T Ravi and Mr. Manish Kumar Jain approved with over 99.99% voting in favor

💡 Track subsequent quarterly earnings for progress on operational turnaround and observe execution details of related-party business with IPCA Laboratories.

Krebs Biochemicals Closes Trading Window from September 30, 2026 for Q2 FY27 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 21 Sep 2026, 12:02 PM

Krebs Biochemicals & Industries Limited announced the closure of its trading window for insiders pursuant to SEBI regulations. The window will close from the close of business hours on September 30, 2026, and remain closed until 48 hours after the declaration of the Unaudited Financial Results for Q2 and H1 ended September 30, 2026. The date of the Board meeting to consider the financial results will be intimated in due course.

Trading window closes effective September 30, 2026 at close of business hours
Closure will remain until 48 hours after declaration of Q2 and H1 results
Applicable to promoters, directors, designated persons, and connected persons
Board meeting date to declare results to be announced in due course

💡 Track the upcoming exchange filing for the announcement of the Board meeting date to consider Q2 FY27 financial results.

Q1 FY27 Net Loss Narrows to ₹2.48 Cr; Revenue Up 27.4% YoY to ₹6.98 Cr

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 07 Sep 2026, 02:45 PM

Krebs Biochemicals reported a 27.4% YoY increase in revenue from operations to ₹6.98 Cr (₹698.35 lacs) for Q1 ended June 30, 2026, compared to ₹5.48 Cr in Q1 FY26. Net loss narrowed significantly to ₹2.48 Cr from ₹5.32 Cr in the corresponding prior-year quarter. The company continues to face operational headwinds as its Vizag unit remains closed under an Andhra Pradesh Pollution Control Board order dated February 7, 2025. Additionally, the Board had previously approved the amalgamation of the company into Ipca Laboratories Limited (appointed date April 1, 2026), which remains subject to regulatory approvals.

Revenue from operations increased 27.4% YoY to ₹6.98 Cr (₹698.35 lacs) in Q1 FY27 vs ₹5.48 Cr in Q1 FY26
Net loss narrowed to ₹2.48 Cr (₹248.48 lacs) compared to a loss of ₹5.32 Cr in Q1 FY26
Total expenses stood at ₹9.62 Cr (₹962.48 lacs), reduced from ₹10.82 Cr in Q1 FY26
Operations at the Vizag manufacturing unit remain shut following an APPCB closure order dated February 7, 2025
Scheme of amalgamation with Ipca Laboratories Ltd (approved June 26, 2026) is pending necessary regulatory consents

💡 Track progress on the revocation of the APPCB closure order for the Vizag facility and monitor the statutory and shareholder approval milestones for the amalgamation with Ipca Laboratories.

Krebs Biochemicals Schedules 34th AGM on Sept 29, 2026; Reports FY26 Net Loss of ₹16.93 Cr

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Sep 2026, 03:03 PM

Krebs Biochemicals & Industries Limited has issued the notice for its 34th Annual General Meeting (AGM) scheduled for September 29, 2026, via video conferencing. The company's 5-year financial summary in the annual report indicates FY26 total income fell to ₹25.76 Cr from ₹44.02 Cr in FY25, while net loss narrowed to ₹16.93 Cr from ₹26.94 Cr. Net worth remains deeply negative at -₹162.75 Cr against total borrowings of ₹224.84 Cr. Key agenda items include standard ordinary business and approval for related-party transactions with Ipca Laboratories Limited.

34th AGM to be held virtually on September 29, 2026, at 11:30 AM
Remote e-voting window open from September 25, 2026 (9:00 AM) to September 28, 2026 (5:00 PM) with a cut-off date of September 23, 2026
FY26 total income reported at ₹2,575.79 Lakhs (₹25.76 Cr) versus ₹4,402.08 Lakhs in FY25
Net loss for FY26 stood at ₹1,693.31 Lakhs (₹16.93 Cr), bringing negative net worth to -₹16,275.47 Lakhs (-₹162.75 Cr)
Special business includes approval of related-party transactions with promoter entity Ipca Laboratories Limited

💡 Track voting outcomes and management commentary at the September 29 AGM regarding product line diversification and financial support from Ipca Laboratories to address ongoing 'Going Concern' uncertainties.

KREBSBIO Board approves Q1 FY27 results; company faces Rs 225 Cr debt and negative net worth

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 06 Aug 2026, 01:39 PM

Krebs Biochemicals and Industries Limited has approved its unaudited financial results for the quarter ended June 30, 2026. The company remains in a precarious financial position with a negative net worth of Rs 162 Cr and total debt of Rs 225 Cr. Historically, the company has struggled with profitability, reporting a net margin of -62.1% in FY25 and a net loss of Rs 26.92 Cr. Investors should monitor the full results for any signs of a turnaround through new product additions and promoter financial support.

Board meeting concluded at 01:30 p.m. on August 6, 2026, to approve Q1 results.
Company reported a negative net worth of INR 146.24 Cr as of March 31, 2025.
Total debt stands at Rs 225 Cr, significantly impacting the balance sheet stability.
Promoter holding is maintained at 72.7%, providing some assurance of continued support.
Net loss in FY25 widened by 36.5% to INR 26.92 Cr compared to the previous year.

💡 Review the full financial statement to check for any improvement in operating profit margins and whether the auditors have continued the 'Going Concern' qualification.

Routine Compliance: Krebs Bio Submits SEBI Regulation 74(5) Certificate for Q1 FY27

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 02 Jul 2026, 03:40 PM

Krebs Biochemicals has filed its quarterly compliance certificate under SEBI Regulation 74(5) for the period ending June 30, 2026. The document, issued by KFIN Technologies Limited, confirms that security certificates received for dematerialization were processed and the names of depositories were updated in the register of members. This is a standard administrative filing and does not impact the company's financial position or its ongoing 'Going Concern' uncertainty. Investors should note the company's significant financial distress, including a negative net worth of Rs -162 Cr.

Compliance certificate submitted for the quarter ended June 30, 2026
Registrar and Share Transfer Agent (RTA) confirmed as KFIN Technologies Limited
Confirms adherence to SEBI (Depositories and Participants) Regulations, 2018
Company continues to face financial stress with a negative net worth of Rs -162 Cr as per latest context

💡 Focus on upcoming quarterly financial results and any updates regarding the promoter's financial support, as the company currently faces material uncertainty regarding its survival.

Krebs Biochemicals to Merge with Ipca Laboratories; Share Swap Ratio Set at 7:200

🟢 POSITIVE ⭐ 10/10

M&A 📅 26 Jun 2026, 01:20 PM

Krebs Biochemicals & Industries Limited has approved a Scheme of Amalgamation to merge with Ipca Laboratories Limited. Under the proposed scheme, Krebs shareholders will receive 7 equity shares of Ipca Laboratories (Re. 1 each) for every 200 equity shares of Krebs (Rs. 10 each). The merger aims to integrate Krebs' specialized fermentation-based API manufacturing capabilities into Ipca's larger operations to secure supply chains and optimize costs. The appointed date for the merger is April 1, 2026, subject to regulatory and shareholder approvals.

Share swap ratio fixed at 7 shares of Ipca Laboratories for every 200 shares held in Krebs Biochemicals.
Ipca Laboratories reported a standalone total income of ₹7,431 Crores for FY26, while Krebs reported ₹26 Crores.
The merger will provide Ipca with unique fermentation-based API manufacturing facilities that it currently lacks.
Krebs is currently loss-making and will benefit from Ipca's financial strength and R&D capabilities.
The appointed date for the scheme is April 1, 2026, and it remains subject to SEBI and NCLT approvals.

💡 Investors should evaluate the merger based on the current market price of Ipca Laboratories to determine if the 7:200 swap ratio offers a premium over Krebs' current stock price. The merger provides Krebs shareholders an exit into a much larger, diversified, and profitable pharmaceutical entity.

Krebs Biochemicals to Merge with Ipca Laboratories; Share Swap Ratio Set at 7:200

🟢 POSITIVE ⭐ 10/10

M&A 📅 26 Jun 2026, 01:17 PM

The Board of Krebs Biochemicals has approved a Scheme of Amalgamation to merge with Ipca Laboratories Limited to achieve operational synergies and cost optimization. Under the proposed ratio, shareholders of Krebs will receive 7 equity shares of Ipca Laboratories for every 200 shares held in Krebs. Krebs reported a total income of Rs. 26 crore in FY26, which is significantly smaller than Ipca's Rs. 7,431 crore. The merger aims to integrate Krebs' specialized fermentation-based API manufacturing capabilities into Ipca's larger ecosystem, securing supply chains for key therapeutic ingredients.

Share swap ratio of 7 fully paid-up equity shares of Ipca (Re. 1 each) for every 200 shares of Krebs (Rs. 10 each).
Ipca Laboratories reported a standalone total income of Rs. 7,431 crore for FY26 compared to Krebs' Rs. 26 crore.
The merger provides Ipca with fermentation-based API manufacturing facilities that it currently lacks.
The appointed date for the scheme is April 1, 2026, subject to regulatory and shareholder approvals.
Krebs is currently loss-making and unable to fund R&D, which the merger aims to resolve through Ipca's financial strength.

💡 Investors should evaluate the implied value of the merger based on the 7:200 swap ratio relative to current market prices. The merger is generally positive for Krebs shareholders as it provides an exit into a much larger, profitable, and diversified pharmaceutical entity.

Krebs Biochemicals to Close Trading Window from June 30, 2026, for Q1 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 22 Jun 2026, 12:16 PM

Krebs Biochemicals and Industries Limited has announced that its trading window will be closed starting from the close of business hours on June 30, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, for the purpose of considering Unaudited Financial Results for the first quarter ending June 30, 2026. The window will remain closed for all designated persons and their relatives until 48 hours after the financial results are declared. The company will announce the specific date of the Board meeting for result approval in a separate future filing.

Trading window closure effective from the close of business hours on June 30, 2026.
Closure is related to the declaration of Unaudited Financial Results for Q1 ended June 30, 2026.
Restriction applies to promoters, directors, designated persons, and their immediate relatives.
Trading window will reopen 48 hours after the financial results are officially announced to the exchanges.
Board meeting date for result consideration to be intimated in due course.

💡 No action is required as this is a routine regulatory compliance filing; investors should wait for the announcement of the Board meeting date to assess the company's quarterly performance.

Krebs Biochemicals FY26 Revenue Drops 45% to ₹23.7 Cr; Net Loss Narrows to ₹16.9 Cr

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 21 May 2026, 01:33 PM

Krebs Biochemicals reported a sharp 45.2% decline in annual revenue to ₹23.73 crore for FY26, largely due to the continued closure of its Vizag manufacturing unit since February 2025. While the annual net loss narrowed to ₹16.93 crore from ₹26.94 crore in FY25, the company's financial health remains critical with a deeply negative net worth of ₹162.75 crore. Operations at the Vizag plant remain suspended following orders from the Andhra Pradesh Pollution Control Board, significantly impacting production capacity.

Annual revenue from operations fell 45.2% YoY to ₹2,373.16 lacs from ₹4,331.19 lacs.
Net loss for the full year narrowed to ₹1,693.31 lacs compared to a loss of ₹2,693.93 lacs in the previous year.
The Vizag manufacturing unit remains closed since Feb 7, 2025, due to a Pollution Control Board order.
Net worth deteriorated further to negative ₹16,275.47 lacs as of March 31, 2026.
Finance costs rose to ₹708.59 lacs for FY26, up from ₹591.42 lacs in FY25, indicating increasing debt servicing pressure.

💡 Investors should exercise extreme caution due to the company's negative net worth and the ongoing regulatory suspension of its primary manufacturing facility. Avoid fresh positions until there is a clear roadmap for plant reopening and capital restructuring.

Krebs Biochemicals Clarifies No Undisclosed Material Events Behind Recent Price Volatility

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 10 Apr 2026, 05:17 PM

The National Stock Exchange of India (NSE) sought clarification from Krebs Biochemicals and Industries Limited on April 8, 2026, regarding significant movement in its share price. In its formal response on April 10, 2026, the company stated that there is no undisclosed material information or event that has a bearing on the price movement. The management confirmed that all disclosures required under Regulation 30 of SEBI (LODR) Regulations, 2015, have been made. This indicates that the recent price action is likely driven by market factors rather than internal corporate developments.

NSE issued a surveillance query (Ref No.: NSE/CM/Surveillance/16692) on April 8, 2026, regarding price movement.
Company clarified on April 10, 2026, that no material information remains undisclosed to the exchange.
Management reaffirmed compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The response suggests the price movement is not linked to any specific internal corporate event or announcement.

💡 Investors should be cautious as the company has confirmed no fundamental news is driving the recent price movement. The volatility may be speculative, and decisions should be based on existing financial performance rather than recent price trends.

Krebs Biochemicals to Close Trading Window from March 31, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 19 Mar 2026, 10:51 AM

Krebs Biochemicals and Industries Limited has announced the closure of its trading window effective from the close of business hours on March 31, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations for the purpose of finalising audited financial results. The window will remain closed until 48 hours after the declaration of the Audited Financial Results for the fourth quarter and the full year ending March 31, 2026. The specific date for the board meeting to approve these results will be announced at a later date.

Trading window closure begins from the close of business hours on March 31, 2026.
Applies to all promoters, directors, designated persons, and their immediate relatives.
Window will reopen 48 hours after the announcement of Q4 and FY2026 audited financial results.
Board meeting date for result consideration to be intimated in due course.

💡 This is a routine regulatory announcement and does not require any immediate action from retail investors. Focus should remain on the upcoming financial results when they are released.

Krebs Biochemicals Q3 Loss Narrows to ₹3.13 Cr; Revenue Declines 36% YoY

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 01:33 PM

Krebs Biochemicals reported a sharp 36.6% YoY decline in revenue from operations to ₹7.27 crore for the quarter ended December 31, 2025. Despite the revenue drop, the company narrowed its net loss to ₹3.13 crore from ₹7.74 crore in the previous year's corresponding quarter, largely due to a significant reduction in operating expenses. A major operational headwind persists as the Vizag manufacturing unit remains closed following a February 2025 order from the Andhra Pradesh Pollution Control Board. The company's financial position is critical, with a negative net worth of ₹160.83 crore and total borrowings exceeding ₹221 crore.

Revenue from operations fell to ₹727.42 lacs in Q3 FY26 compared to ₹1,146.72 lacs in Q3 FY25.
Net loss for the quarter narrowed to ₹312.65 lacs from ₹773.89 lacs YoY.
Total expenses were reduced by approximately 46% YoY to ₹1,040.49 lacs.
The Vizag manufacturing unit remains shut down since February 7, 2025, due to regulatory orders.
Company reports a deeply negative net worth of ₹16,083.25 lacs as of December 31, 2025.

💡 Investors should remain highly cautious as the company faces severe financial distress with negative net worth and ongoing regulatory issues at its Vizag plant. The significant drop in revenue and high debt levels make this a high-risk situation despite the narrowing of quarterly losses.

Krebs Biochemicals Reports Nil Physical Share Transfer Re-lodgement Requests for Dec 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 05 Jan 2026, 10:22 AM

Krebs Biochemicals and Industries Limited has submitted its monthly report regarding the re-lodgement of transfer requests for physical shares as per SEBI guidelines. For the month ending December 31, 2025, the company's Registrar, KFIN Technologies, reported that zero requests were received or processed. This disclosure is part of a special six-month window mandated by SEBI which ran from July 7, 2025, to January 6, 2026. The filing is a routine regulatory update and does not impact the company's financial or operational standing.

Zero (NIL) requests received for re-lodgement of physical share transfers during December 2025.
Compliance follows SEBI Circular SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated July 2, 2025.
The special window for physical share transfer re-lodgement was active from July 7, 2025, to January 6, 2026.
KFIN Technologies Limited confirmed the status as the company's Registrar and Share Transfer Agent.

💡 No action is required from investors as this is a routine compliance filing. Shareholders still holding physical certificates are encouraged to dematerialize their holdings for easier liquidity.

Krebs Biochemicals Files SEBI Regulation 74(5) Compliance for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 02 Jan 2026, 10:58 AM

Krebs Biochemicals has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI Regulations for the period ending December 31, 2025. The document confirms that KFIN Technologies Limited, the company's Registrar and Share Transfer Agent, has processed all dematerialization and rematerialization requests. These details have been duly reported to both the BSE and NSE. This filing is a mandatory procedural requirement to ensure accurate shareholding records across depositories.

Compliance certificate issued for the quarter ended December 31, 2025.
KFIN Technologies Limited confirmed processing of demat and remat requests.
Filing covers requirements for both NSDL and CDSL depositories.
The company is listed on both BSE (524518) and NSE (KREBSBIO).

💡 This is a routine administrative filing with no impact on company fundamentals. Investors should continue to monitor the company's operational performance and upcoming earnings reports.

View All KREBSBIO Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue from operations fell 14.1% YoY to INR 43.31 Cr in FY25 from INR 50.42 Cr in FY24. Segment-specific growth percentages are not disclosed in available documents.

Profitability Margins

Net margin is deeply negative at -62.1% for FY25, worsening from -39.1% in FY24. The company incurred a net loss of INR 26.92 Cr in FY25, which widened by 36.5% compared to the INR 19.73 Cr loss in FY24 due to declining revenue and rising finance costs.

EBITDA Margin

EBITDA margin is negative at -33.1% for FY25. Core profitability is under severe pressure as total expenses of INR 70.94 Cr significantly exceed total income of INR 44.02 Cr.

Capital Expenditure

Property, Plant and Equipment stood at INR 145.23 Cr as of March 31, 2025. Capital Work in Progress (CWIP) increased to INR 1.24 Cr from INR 0.16 Cr, indicating minor ongoing investments.

Credit Rating & Borrowing

Borrowing costs (finance costs) increased by 26.1% YoY to INR 5.91 Cr in FY25 from INR 4.69 Cr in FY24. Specific credit ratings and interest rate percentages are not disclosed in available documents.

⚙️ Operational Drivers

Capacity Expansion

Current installed capacity is not disclosed. The company plans to achieve break-even through the addition of new products being manufactured, supported by the Principal Promoter Shareholder.

Raw Material Costs

Cost of materials consumed was INR 2.49 Cr in FY25, representing 5.7% of revenue. This was a 54.1% decrease from INR 5.43 Cr in FY24, likely due to reduced production volumes.

📈 Strategic Growth

Growth Strategy

The company aims to achieve break-even by adding new products to its manufacturing portfolio and leveraging marketing and financial support from its Principal Promoter Shareholder. The promoter has provided a confirmation of financial support to meet obligations and turnaround operations.

Products & Services

Biochemical products and API intermediates developed through biochemistry processes.

New Products/Services

Management plans to add new products to the manufacturing line to drive a turnaround, though specific revenue contribution percentages are not disclosed.

Strategic Alliances

The company relies on a strategic support arrangement with its Principal Promoter Shareholder for financial needs and marketing support.

🌍 External Factors

Industry Trends

The industry is characterized by cyclical demand and pricing. The company is positioning itself for a turnaround by diversifying its product range and relying on promoter-backed marketing support to navigate competitive capacity increases.

Competitive Landscape

The company faces significant competition from players with increased installed capacity, which impacts pricing and market share.

Competitive Moat

The company's moat is not clearly established in the documents, as it currently faces material uncertainty regarding its ability to continue as a going concern due to a negative net worth of INR 146.24 Cr.

Macro Economic Sensitivity

The business is highly sensitive to the global economy and cyclical demand for biochemical products. Any global incident affecting world markets directly impacts operations.

Geopolitical Risks

Geopolitical risks and world market incidents are cited as factors that could materially affect the company's operations and financial presumptions.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to changes in government regulations and tax regimes, which can materially affect financial performance.

Legal Contingencies

The company has disclosed the impact of pending litigations on its financial position in Note 32 of the standalone financial statements. Specific case values are not provided in the summary.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the 'Going Concern' status. Total liabilities exceeded total assets by INR 146.24 Cr as of March 31, 2025 (up from INR 119.22 Cr in FY24), creating a material uncertainty about the company's survival without continuous promoter support.

Third Party Dependencies

High dependency on the Principal Promoter Shareholder for financial liquidity and marketing support to continue operations.

Credit & Counterparty Risk

Trade receivables dropped by 97.4% to INR 0.05 Cr in FY25 from INR 1.90 Cr in FY24, which may indicate a shift in credit terms or a significant reduction in credit-based sales.